The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Novel treatment regimens under investigation for Richter’s transformation
Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses the treatment strategies under investigation to enhance outcomes for patients with Richter’s transformation (RT), who currently have a poor prognosis. Several studies, such as the Phase II RT1 (NCT04271956) trial of tislelizumab plus zanubrutinib and the MOLTO trial (NCT04082897) of atezolizumab with obinutuzumab and venetoclax, have demonstrated the potential utility of PD-1 inhibition. Dr Hampel is also involved in a study of durvalumab with acalabrutinib and venetoclax in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
